Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein

被引:24
作者
Chandrasekaran, Vasu
Ambati, Jayakrishna
Ambati, Balamurali K.
Taylor, Ethan Will [1 ]
机构
[1] Univ N Carolina, Res Off, Mol Med Lab, Greensboro, NC 27402 USA
[2] Univ Kentucky, Dept Ophthalmol, Lexington, KY 40536 USA
[3] Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA
关键词
angiogenesis; vascular endothelial growth factor (VEGF); SPARC; tumor progression/suppression; protein-protein docking; structure prediction;
D O I
10.1016/j.jmgm.2007.05.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The extracellular module of SPARC/osteonectin binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-stimulated proliferation of endothelial cells. In an attempt to identify the binding site for SPARC on VEGF, we hypothesized that this binding site could overlap at least partially the binding site of VEGF receptor I (VEGFR-1), as SPARC acts by preventing VEGF-induced phosphorylation of VEGFR-1. To this end, a docking simulation was carried out using a predictive docking tool to obtain modeled structures of the VEGF-SPARC complex. The predicted structure of VEGF-SPARC complex indicates that the extracellular domain of SPARC interacts with the VEGFR-I binding site of VEGF, and is consistent with known biochemical data. Following molecular dynamics refinement, side-chain interactions at the protein interface were identified that were predicted to contribute substantially to the free energy of binding. These provide a detailed prediction of key amino acid side-chain interactions at the protein-protein interface. To validate the model further, the identified interactions will be used for designing mutagenesis studies to investigate their effect on binding activity. This model of the VEGF-SPARC complex should provide a basis for future studies aimed at identifying inhibitors of VEGF-induced angiogenesis. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 59 条
[1]   Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies [J].
Aiello, LP .
OPHTHALMIC RESEARCH, 1997, 29 (05) :354-362
[2]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[3]  
[Anonymous], SCI STKE
[4]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[5]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[6]   Matricellular proteins: extracellular modulators of cell function [J].
Bornstein, P ;
Sage, EH .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (05) :608-616
[7]   SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury [J].
Bradshaw, AD ;
Sage, EH .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) :1049-1054
[8]   SPARC, a matricellular protein: at the crossroads of cell-matrix [J].
Brekken, RA ;
Sage, EH .
MATRIX BIOLOGY, 2000, 19 (07) :569-580
[9]  
CASE DA, 2002, AMBER, V7
[10]   SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix [J].
Chlenski, A ;
Liu, SQ ;
Guerrero, LJ ;
Yang, QW ;
Tian, YF ;
Salwen, HR ;
Zage, P ;
Cohn, SL .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) :310-316